Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|1|3|217-235

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.1, Iss.3, 2006-09, pp. : 217-235

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proapoptotische Therapie mit Oblimersen (bcl-2-Antisense-Oligonukleotid) – Übersicht über präklinische und klinische Daten

By  

Oncology Research and Treatment, Vol. 26, Iss. 7, 2004-11 ,pp. : 60-69

Karger

Access to resources Recommend Favorite

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Trials of Targeted Alpha Therapy for Cancer

By  

Reviews on Recent Clinical Trials, Vol. 3, Iss. 3, 2008-09 ,pp. : 185-191

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy in HER2-Positive Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Targeted Therapy of HER2-Negative Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite